{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:44:25Z","timestamp":1783021465599,"version":"3.54.6"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Pathologie"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.annpat.2024.09.015","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T16:47:46Z","timestamp":1729097266000},"page":"407-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aspects cliniques des amyloses syst\u00e9miques en 2024"],"prefix":"10.1016","volume":"44","author":[{"given":"Sophie","family":"Georgin-Lavialle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Grateau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annpat.2024.09.015_bib0310","first-page":"165","article-title":"Amyloidosis from the patient perspective: the French daily impact of amyloidosis study","volume":"29","author":"Damy","year":"2022","journal-title":"Amyloid Int J Exp Clin Investig"},{"key":"10.1016\/j.annpat.2024.09.015_bib0315","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13023-023-02933-w","article-title":"Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases","volume":"18","author":"Damy","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.annpat.2024.09.015_bib0320","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.revmed.2007.01.005","article-title":"Les amyloses multisyst\u00e9miques en 2007","volume":"28","author":"Grateau","year":"2007","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annpat.2024.09.015_bib0325","first-page":"164","article-title":"Amyloidosis physiopathology","volume":"67","author":"Grateau","year":"2000","journal-title":"Joint Bone Spine Rev Rhum"},{"key":"10.1016\/j.annpat.2024.09.015_bib0330","first-page":"1546","article-title":"Cardiac transthyretin amyloidosis","volume":"98","author":"Dungu","year":"2012","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.annpat.2024.09.015_bib0335","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cpcardiol.2012.11.002","article-title":"Current trends in diagnosis and management of cardiac amyloidosis","volume":"38","author":"Esplin","year":"2013","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.annpat.2024.09.015_bib0340","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1474-4422(23)00334-4","article-title":"Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment","volume":"22","author":"Adams","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.annpat.2024.09.015_bib0345","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.annpat.2024.09.015_bib0350","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.annpat.2024.09.015_bib0355","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjmed.2011.04.013","article-title":"Cardiac amyloidosis: a practical approach to diagnosis and management","volume":"124","author":"Kapoor","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0360","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.annpat.2024.09.015_bib0365","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annpat.2024.09.015_bib0370","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1002\/ehf2.13652","article-title":"History of extracardiac\/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis","volume":"8","author":"Kharoubi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.annpat.2024.09.015_bib0375","first-page":"234","article-title":"Association between hearing loss and hereditary ATTR amyloidosis","volume":"26","author":"Bartier","year":"2019","journal-title":"Amyloid Int J Exp Clin Investig"},{"key":"10.1016\/j.annpat.2024.09.015_bib0380","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.acvd.2023.07.003","article-title":"Changes in amyloidosis phenotype over 11\u00a0years in a cardiac amyloidosis referral centre cohort in France","volume":"116","author":"Damy","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.annpat.2024.09.015_bib0385","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/joim.13222","article-title":"Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis","volume":"289","author":"Eldhagen","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0390","first-page":"226","article-title":"Association between spinal stenosis and wild-type ATTR amyloidosis","volume":"28","author":"Godara","year":"2021","journal-title":"Amyloid Int J Exp Clin Investig"},{"key":"10.1016\/j.annpat.2024.09.015_bib0395","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.annpat.2024.09.015_bib0400","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/hrt.2005.061911","article-title":"Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance","volume":"92","author":"Perugini","year":"2006","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.annpat.2024.09.015_bib0405","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annpat.2024.09.015_bib0410","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41431-019-0337-1","article-title":"Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data","volume":"27","author":"Lahuerta Pueyo","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.annpat.2024.09.015_bib0415","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ane.13035","article-title":"Hereditary transthyretin-related amyloidosis","volume":"139","author":"Finsterer","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.annpat.2024.09.015_bib0420","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.annpat.2024.09.015_bib0425","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0430","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0435","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20\u00a0years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.annpat.2024.09.015_bib0440","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2014.08.003","article-title":"Amylose AL","volume":"36","author":"Jaccard","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annpat.2024.09.015_bib0445","first-page":"1137","article-title":"Amylose AL, du diagnostic au traitement","volume":"70","author":"Villesuzanne","year":"2020","journal-title":"Rev Prat"},{"key":"10.1016\/j.annpat.2024.09.015_bib0450","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.annpat.2024.09.015_bib0455","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.annpat.2024.09.015_bib0460","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346\u00a0patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.annpat.2024.09.015_bib0465","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2024.09.015_bib0470","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.annpat.2024.09.015_bib0475","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejim.2013.10.007","article-title":"Systemic amyloidoses: what an internist should know","volume":"24","author":"Palladini","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0480","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.annpat.2024.09.015_bib0485","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annpat.2024.09.015_bib0490","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.berh.2012.07.003","article-title":"Osteo-articular manifestations of amyloidosis","volume":"26","author":"M\u2019bapp\u00e9","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.annpat.2024.09.015_bib0495","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3390\/jcm12041624","article-title":"The landscape of cytogenetic aberrations in light-chain amyloidosis with or without coexistent multiple myeloma","volume":"12","author":"He","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0500","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-023-00945-0","article-title":"Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies","volume":"13","author":"Bal","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annpat.2024.09.015_bib0505","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annpat.2024.09.015_bib0510","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.annpat.2024.09.015_bib0515","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3390\/jcm13061744","article-title":"Renal AL amyloidosis: amyloidosis: updates on diagnosis, staging, and management","volume":"13","author":"Shafqat","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0520","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.annpat.2024.09.015_bib0525","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-023-00789-8","article-title":"The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004\u00a0and 2018","volume":"13","author":"Palladini","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annpat.2024.09.015_bib0530","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.annpat.2024.09.015_bib0535","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346\u00a0patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.annpat.2024.09.015_bib0540","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa070484","article-title":"High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis","volume":"357","author":"Jaccard","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0545","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0550","first-page":"162","article-title":"Changing epidemiology of AA amyloidosis: clinical observations over 25\u00a0years at a single national referral centre","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid Int J Exp Clin Investig"},{"key":"10.1016\/j.annpat.2024.09.015_bib0555","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/art.37827","article-title":"AA amyloidosis complicating the hereditary periodic fever syndromes","volume":"65","author":"Lane","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.annpat.2024.09.015_bib0560","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2169\/internalmedicine.1099-18","article-title":"First nationwide survey of 199\u00a0patients with amyloid A amyloidosis in Japan","volume":"57","author":"Okuda","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0565","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0570","first-page":"1","article-title":"Risk factors for AA amyloidosis in Germany","volume":"22","author":"Blank","year":"2015","journal-title":"Amyloid Int J Exp Clin Investig"},{"key":"10.1016\/j.annpat.2024.09.015_bib0575","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.ejim.2017.02.004","article-title":"AA amyloidosis is an emerging cause of nephropathy in obese patients","volume":"39","author":"Stankovic Stojanovic","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0580","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.revmed.2022.12.004","article-title":"French practical guidelines for the diagnosis and management of AA amyloidosis","volume":"44","author":"Georgin-Lavialle","year":"2023","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annpat.2024.09.015_bib0585","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/jcm10091983","article-title":"Amyloid goiter in familial mediterranean fever: description of 42\u00a0Cases from a French Cohort and from Literature Review","volume":"10","author":"Vergneault","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.annpat.2024.09.015_bib0590","first-page":"84","article-title":"AA amyloidosis treated with tocilizumab: case series and updated literature review","volume":"22","author":"Courties","year":"2015","journal-title":"Amyloid Int J Exp Clin Investig"},{"key":"10.1016\/j.annpat.2024.09.015_bib0595","first-page":"1200","article-title":"bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease","volume":"83","author":"Kvacskay","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annpat.2024.09.015_bib0600","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1681\/ASN.0000000000000339","article-title":"Development and validation of staging systems for AA amyloidosis","volume":"35","author":"Basset","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.annpat.2024.09.015_bib0605","first-page":"189","article-title":"Safety and efficacy of empirical interleukin-1\u00a0inhibition using anakinra in AA amyloidosis of uncertain aetiology","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid Int J Exp Clin Investig"},{"key":"10.1016\/j.annpat.2024.09.015_bib0305","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.ajkd.2023.07.020","article-title":"Kidney Transplantation in patients with AA amyloidosis: outcomes in a french multicenter cohort","volume":"83","author":"Schwarz","year":"2024","journal-title":"Am J Kidney Dis"}],"container-title":["Annales de Pathologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649824002037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0242649824002037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T22:28:32Z","timestamp":1730932112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0242649824002037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0242649824002037"],"URL":"https:\/\/doi.org\/10.1016\/j.annpat.2024.09.015","relation":{},"ISSN":["0242-6498"],"issn-type":[{"value":"0242-6498","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspects cliniques des amyloses syst\u00e9miques en 2024","name":"articletitle","label":"Article Title"},{"value":"Annales de Pathologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annpat.2024.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}